Results 191 to 200 of about 5,065,448 (337)
Immune response and prevalence of antibody to Norwalk enteritis virus as determined by radioimmunoassay [PDF]
Neil R. Blacklow +6 more
openalex +1 more source
CDK11 inhibition stabilises the tumour suppressor p53 and triggers the production of an alternative p21WAF1 splice variant p21L, through the inactivation of the spliceosomal protein SF3B1. Unlike the canonical p21WAF1 protein, p21L is localised in the cytoplasm and has reduced cell cycle‐blocking activity.
Radovan Krejcir +12 more
wiley +1 more source
The progression of maternal RSV antibodies in the offspring [PDF]
Mustafa Hacımustafaoğlu
openalex +1 more source
J. Hollowell +6 more
semanticscholar +1 more source
A mouse model for vascular normalization and a human breast cancer cohort were studied to understand the relationship between vascular leakage and tumor immune suppression. For this, endothelial and immune cell RNAseq, staining for vascular function, and immune cell profiling were employed.
Liqun He +8 more
wiley +1 more source
Listening to Luddites: Innovation Antibodies and Corporate Success [PDF]
Protracted innovation is an essential activity of every organization in the modern global marketplace and is fueled by a continuous stream of fresh ideas.
Gary OSTER
core
A novel anti-EMMPRIN function-blocking antibody reduces T cell proliferation and neurotoxicity: relevance to multiple sclerosis [PDF]
Smriti Agrawal +4 more
openalex +1 more source
Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies
J. Dalmau +9 more
semanticscholar +1 more source
Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia +9 more
wiley +1 more source
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz +15 more
wiley +1 more source

